ijms-logo

Journal Browser

Journal Browser

Peculiarities of Transcription Factors in Cancer for the Development of Novel Therapies

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (31 August 2021) | Viewed by 2737

Special Issue Editor

Department of Molecular, Cellular, and Biomedical Sciences, University of New Hampshire, Durham, NH 03824, USA
Interests: breast and ovarian cancer; drug discovery; transcription factors; metastasis; chemoresistance
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Transcription factors are often inappropriately expressed or activated in cancer, and cancer cells often become addicted to these transcription factors. Additionally, transcription factors often serve as a convergence point of many upstream signaling pathways. Taken together, this suggests that targeting transcription factors would be beneficial for cancer therapy. While some transcription factors, such as nuclear hormone receptors, have been successfully targeted in cancer, most other transcription factors remain difficult to target.

This Special Issue of the International Journal of Molecular Sciences, entitled “Peculiarities of Transcription Factors in Cancer for the Development of Novel Therapies”, aims to identify new features of transcription factors in cancer that may promote their druggability, to identify new drugs or treatment strategies targeting transcription factors, and to examine the current methods used to identify novel therapies targeting transcription factors.

The formats for publication include original research articles and reviews.

Prof. Dr. Sarah Walker
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • transcription factors
  • proteomics
  • genomics
  • drug discovery
  • gene expression
  • cancer

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 3828 KiB  
Article
Twist1 Influences the Expression of Leading Members of the IL-17 Signaling Pathway in HER2-Positive Breast Cancer Cells
by Bruno R. B. Pires, Renata Binato, Gerson M. Ferreira, Stephany Corrêa, Bárbara Du Rocher, Daniel Bulzico, Susanne Crocamo, Everton Cruz dos Santos, Luize G. Lima and Eliana Abdelhay
Int. J. Mol. Sci. 2021, 22(22), 12144; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms222212144 - 10 Nov 2021
Cited by 2 | Viewed by 2155
Abstract
Breast cancer (BC) is a heterogeneous disease composed of multiple subtypes with different molecular characteristics and clinical outcomes. The metastatic process in BC depends on the transcription factors (TFs) related to epithelial-mesenchymal transition (EMT), including the master regulator Twist1. However, its role beyond [...] Read more.
Breast cancer (BC) is a heterogeneous disease composed of multiple subtypes with different molecular characteristics and clinical outcomes. The metastatic process in BC depends on the transcription factors (TFs) related to epithelial-mesenchymal transition (EMT), including the master regulator Twist1. However, its role beyond EMT in BC subtypes remains unclear. Our study aimed to investigate the role of Twist1, beyond EMT, in the molecular subtypes of BC. In patients, we observed the overexpression of TWIST1 in the HER2+ group. The silencing of TWIST1 in HER2+ BC cells resulted in the upregulation of 138 genes and the downregulation of 174 genes compared to control cells in a microarray assay. In silico analysis revealed correlations between Twist1 and important biological processes such as the Th17-mediated immune response, suggesting that Twist1 could be relevant for IL-17 signaling in HER2+ BC. IL-17 signaling was then examined, and it was shown that TWIST1 knockdown caused the downregulation of leading members of IL-17 signaling pathway. Taken together, our findings suggest that Twist1 plays a role on IL-17 signaling in HER2+ BC. Full article
Show Figures

Figure 1

Back to TopTop